Drug Development, Treatment, Artificial Intelligence, Molecule Engineering and Innovation
OUR STORIES
Medicines matter in everyone's lives
What we’re building can make a real difference
Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board
Pioneering expert in membrane protein structure and function to advise Verseon on its platform and pipeline development
November 9, 2023
California-based Verseon is Spearheading the New approach to Drug Development
The emergence of completely new drugs to tackle some of the world’s most prevalent diseases have been few and far between. But that could be about to change. Verseon creates drugs atom by atom, using a proprietary technology platform that goes far beyond just the application of AI
September 15, 2023
Faster, better, more productive
[Verseon’s] models for “de novo molecular design” can figure out which molecular structures are most likely to do which things, and they build accordingly
September 13, 2023
Digital CxO Podcast Ep. 50 - AI for the Pharmaceutical Industry
Verseon is changing how completely new medicines get designed, what we can treat and how well we treat them.... The company designs, atom by atom, completely novel drugs that you cannot find with any other method.... They hold the promise of completely changing the standard of care for the diseases they address because of how unique their therapeutic profiles are
July 24, 2023
Why AI alone won't resolve drug discovery challenges
"When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms"
June 21, 2023
Exploring New Chemical Space for the Treatments of Tomorrow
We've seen the benefits of exploring entirely novel chemical entities... We are now entering an exciting new era in drug discovery and development with immense implications for human health.
June 1, 2023
AI in drug development: A reality check
"Existing data... is a small, little tiny pittance compared to the total number of possibilities that one could explore... Asking A.I. trained on that data to suddenly change everything... is more than just asking a lot. It's not possible."
May 25, 2023
Unlocking a Universe of Drug Candidates
Verseon's hybrid physics- and AI-based platform reveals possibilities far outside the Pharma industry's compound libraries
May 4, 2023
Dreaming Up Drugs No One Has Ever Seen
Verseon's physics- and AI-based drug discovery platform is expanding the frontiers of medicine
FEBRUARY 15, 2023
Disruptors Plan a New Dawn for Healthcare Technology
The Business Influencer describes how Verseon’s drug discovery platform is systematically tackling humanity’s major killers
FEBRUARY 3, 2023
What Will it Take for AI to Live Up to its Hype?
Adityo Prakash, CEO of Verseon, discusses how the data currently available to the pharma industry and other challenges limit AI’s ability to help discover novel drugs
JANUARY 31, 2023
Small Data, Big Ambitions
Verseon's combination of physics-based molecular modeling and Extreme Machine Learning promises multiple treatment options for patients who currently have none
JANUARY 11, 2023
Verseon’s New Oral Anticoagulant Drug Candidates Demonstrate Lower Bleeding Risk
Verseon has developed candidates for a next-generation oral anticoagulant that have the potential to prevent unwanted clots while preserving the body’s ability to stop excessive bleeding
December 15, 2022
Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
DECEMBER 14, 2022
Is AI just hype or a real revolution in pharma? It’s complicated
Verseon's CEO Adityo Prakash discusses the challenges and opportunities facing AI in drug discovery
NOVEMBER 17, 2022
Why there's more to life than making it to a ripe old age
The National describes how Verseon's drug programs place the company at the vanguard of preventing the chronic diseases and disabilities of ageing
NOVEMBER 4, 2022
Verseon Acquires Edammo to Deepen Drug Discovery Approach
Verseon deepens its AI capabilities by acquiring company focused on analyzing the "Small and Wide Data" typical in drug discovery
October 18, 2022
Exploring the Uncharted Chemical Universe for New Medicines
David Kita, Verseon’s CSO, shares his views on the future of computational drug discovery
September 28, 2022
No, AI by Itself Probably Won't Revolutionize Drug Development
Alphabet's DeepMind admits they can't predict drug-protein interactions; "It's just hype," says Adityo Prakash, Verseon's CEO
September 24, 2022
Verseon's PKIs to Battle Diabetic Vision Loss
Verseon's scientists consistently find unique drug candidates that have never been designed or synthesised by anyone else
September 22, 2022
Verseon's HAE Drug Candidates in Focus
Verseon's oral drug candidates will offer an alternative to injections for a rare but potentially fatal condition
September 16, 2022
Verseon Gains European Patent Protection for Potential Sight and Life-Saving Treatments
"These novel compounds ... could help hundreds of millions of people around the world," says David Kita, Verseon's CSO
September 7, 2022
Challenges Facing AI in Drug Discovery
Adityo Prakash, Verseon’s CEO, discusses the way forward
September 1, 2022
Why AI Alone Won’t Solve Drug Discovery
“People are saying, ‘Oh, AI will solve everything.’ It’s just hype,” says Adityo Prakash, Verseon's CEO to Datanami's Alex Woodie
August 30, 2022
Overcoming the Limitations of Drug Discovery AI
"For the foreseeable future, there will simply not be enough experimental binding data available for AI models to reliably predict truly novel, potent, and selective small molecule drug candidates."
July 11, 2022
BioSpace Says Verseon Is "Changing the Paradigm of Drug Discovery"
“What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules.”
MAY 03, 2022
Why AI Alone Cannot Find Tomorrow’s Medicines
“AI is good at interpolating features within the bounds of a well-explored pool of training data but unable to make useful extrapolations far outside it."
April 27, 2022
Impact Wealth Magazine Hails Verseon as the Company Redefining Delay, Prevention, and Treatment of Disease
"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."
April 11, 2022
Verseon’s Kevin Short Speaks with Pharmaceutical Technology Magazine About the Utility of Data and AI in Medicinal Chemistry
“As we collect much larger and more complex data sets from increasingly advanced functionally predictive assays, machine-learning tools could potentially make medicinal chemistry operations more efficient.”
April 2, 2022
MarkTechPost Features Verseon in Latest Issue of AI in Healthcare Magazine
Interview with Verseon CEO Adityo covers challenges in small-molecule drug discovery and what Verseon is doing to address them, spanning advances in fundamental science and AI.
March 30, 2022
Dr. Sangtae Kim to Lead Verseon’s New AI and Data-Science Initiative as CTO
Accomplished veteran of pharmaceutical industry and academia joins Verseon's senior executive team
January 12, 2022
Verseon's Anirban Datta Explains Challenges for Current Antiviral Drugs and Vaccines
Company suggests focusing on host-centric approach for a new class of antivirals as a lasting solution to combat SARS-CoV-2 and other viruses
January 11, 2022
Verseon's Unique Physics- & AI-based Platform Highlighted in Nano Magazine Feature on the Future of Drug Discovery
Comprehensive drug design & development platform praised for its ability to systematically generate multiple chemically distinct candidates in each program
December 15, 2021
Verseon Nominates Primary Drug Candidate for Oral Prophylactic Treatment of the Most Common Cause of Diabetic Vision Loss
Precision-engineered by Verseon's unique computational platform, VE-4840 advances as primary development candidate after key in vivo and preliminary toxicology studies
August 5, 2021
Verseon's Diabetic Retinopathy Drug Candidate Hits Key Milestone, Demonstrating Significant Reduction of Retinal Vascular Permeability
An in vivo efficacy study strongly suggests that drug candidate VE-4840 mitigates damage to retinal blood vessels—a milestone in establishing the compound’s effectiveness as an oral treatment of diabetic retinopathy
May 5, 2021
Verseon's Patent Portfolio Continues to Grow as Platform Produces New Family of Novel Potential Drugs
Receipt of European patent for innovative thrombin inhibitors underscores the power of Verseon's systematic drug design technologies
January 12, 2021
Wellcome and Allergan Veteran Trevor M. Jones Joins Verseon’s Scientific Advisory Board
New addition to company's advisors brings extensive drug research and development experience to the role
November 30, 2020
Verseon Announces Program Targeting Aggressive Metastatic Cancer
The company's third cancer program targets an overexpressed protease on the surface of many solid-tumor cancer cells
September 30, 2020
Journal Thrombosis Research Publishes Peer Reviewed Results Demonstrating Efficacy and Reduced Bleeding Risk for Verseon Anticoagulant VE-1902
New class of anticoagulant drug candidates demonstrates a unique combination of efficacy with lower bleeding in preclinical testing
April 20, 2020
Dean of Harvard School of Engineering Joins Verseon's Scientific Advisory Board
Frank Doyle, Dean of Harvard’s School of Engineering and Applied Sciences, brings fresh perspective to complement Verseon's team of advisors
February 24, 2020
Want to get in touch?
Continue to
Contact
November 9, 2023
